NASDAQ:CRDF • US14147L1089
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARDIFF ONCOLOGY INC (CRDF).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-08 | Ladenburg Thalmann | Initiate | Buy |
| 2025-06-24 | Jefferies | Initiate | Hold |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-06 | Craig-Hallum | Initiate | Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-29 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-16 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-13 | Piper Sandler | Maintains | Overweight |
| 2022-08-29 | Baird | Maintains | Outperform |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-08 | Baird | Initiate | Outperform |
| 2021-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 488K 25.13% | 683K 39.96% | 593K -13.18% | 408.724K -31.08% | 251.359K -38.50% | 102K -59.42% | 110.14M 107,880.39% | 344.37M 212.67% | 714.62M 107.52% | 1.075B 50.43% | 1.465B 36.28% | |
| EBITDA YoY % growth | -45.014M -13.50% | -48.247M -7.18% | -48.596M -0.72% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -45.412M -13.81% | -48.651M -7.13% | -48.96M -0.64% | -50.647M -3.45% | -69.45M -37.12% | -124.461M -79.21% | -111.729M 10.23% | -8.097M 92.75% | 377.3M 4,759.50% | 720.04M 90.84% | 1.097B 52.35% | |
| Operating Margin | -9,305.74% | -7,123.13% | -8,256.32% | -12,391.51% | -27,629.70% | -122,020.60% | -101.44% | -2.35% | 52.80% | 66.98% | 74.88% | |
| EPS YoY % growth | -0.93 -4.49% | -0.95 -2.15% | -0.69 27.37% | -0.60 12.83% | -0.79 -31.85% | -1.15 -45.25% | -1.21 -4.93% | -0.08 93.25% | 0.57 800.00% | 1.46 155.36% | 2.31 58.04% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 31.34% | -0.14 35.04% | -0.19 -14.40% | -0.21 -87.77% | -0.22 -63.41% | -0.23 -68.22% | -0.23 -20.63% | -0.24 -18.52% | -0.28 -22.73% | -0.32 -37.78% | -0.34 -43.48% |
| Revenue Q2Q % growth | 86.7K -20.46% | 88.403K -26.94% | 81.6K -32.00% | 81.6K -66.42% | 102K 17.65% | 102K 15.38% | 102K 25.00% | 102K 25.00% | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.096M 22.85% | -11.799M 20.15% | -15.298M -27.76% | -16.349M -108.87% | -18.768M -69.15% | -19.788M -67.71% | -20.808M -36.02% | -21.318M -30.40% | N/A | N/A | N/A |
All data in USD
14 analysts have analysed CRDF and the average price target is 10.58 USD. This implies a price increase of 528.04% is expected in the next year compared to the current price of 1.685.
CARDIFF ONCOLOGY INC (CRDF) will report earnings on 2026-05-06, after the market close.
The consensus EPS estimate for the next earnings of CARDIFF ONCOLOGY INC (CRDF) is -0.14 USD and the consensus revenue estimate is 86.70K USD.
The number of analysts covering CARDIFF ONCOLOGY INC (CRDF) is 14.